Atomo Diagnostics Limited (ASX:AT1): Integrated Blood Collection Technology and FY26 Performance

Aditi Sarkar

14 October 2026 08:15 PM AEDT

Atomo Diagnostics Limited (ASX:AT1): Integrated Blood Collection Technology and FY26 Performance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Atomo integrates capillary blood collection and delivery into rapid diagnostic test devices.
The Galileo platform combines a safety lancet with sequenced testing steps.
FY26 revenue from ordinary activities increased 41% to AUD5,333,849.
The FY26 loss after tax narrowed to AUD3,513,587.
Year-end cash was AUD3,708,792, while operating cash outflows totalled AUD3,367,965.

Atomo Diagnostics Limited (ASX:AT1) develops integrated rapid diagnostic testing devices designed to simplify sample collection and delivery for professional and self-testing applications. Its Galileo technology combines a safety lancet, capillary blood collection and controlled sample transfer within one device. The company’s FY26 disclosures also show higher reported revenue alongside continuing operating cash use, placing device commercialisation and working-capital requirements in focus.

How Galileo Integrates the Testing Process

The AtomoRapid Galileo platform brings a retracting safety lancet, blood collection and transfer to the test strip into one handheld product. According to the company, its interlocked steps guide the testing sequence and are designed to reduce handling mistakes. The system accommodates lateral-flow test strips using capillary blood, making the collection mechanism relevant to both professional point-of-care and self-test formats.

For Atomo Diagnostics Limited (ASX:AT1), integrated sample handling is a product-design feature rather than evidence that every diagnostic application has achieved a particular clinical outcome. The company describes its blood collection unit as improving volume accuracy, while controlled transfer directs blood to the appropriate area of the test strip. Performance in a specific diagnostic application depends on that test’s own validation and regulatory status.

FY26 Revenue and Reported Loss

Atomo Diagnostics Limited (ASX:AT1) reported revenue from ordinary activities of AUD5,333,849 for the year ended 30 June 2026, representing a 41% increase. The loss after tax attributable to owners declined 29% to AUD3,513,587, compared with AUD4,970,934 in FY25. These figures distinguish revenue expansion from profitability: despite a narrower loss, the business remained loss-making during FY26.

The FY26 annual report also recorded a basic loss per share of 0.425 cents, against 0.768 cents in FY25. No dividends were paid, recommended or declared for the reporting period. These disclosures establish the reported financial position without attributing changes to individual product contracts for which a quantified contribution is not established here.

Operating Cash Flows and Funding

The FY26 statement of cash flows shows that Atomo Diagnostics Limited (ASX:AT1) used AUD3,367,965 in operating activities, compared with AUD1,958,817 in FY25. Payments to suppliers and employees were AUD9,600,684, while customer receipts including GST were AUD4,622,048. Research and development and other government grants received amounted to AUD1,535,515.

Net financing inflows of AUD3,814,802 included proceeds from issuing shares, after transaction costs. Atomo Diagnostics Limited (ASX:AT1) finished 30 June 2026 with cash and cash equivalents of AUD3,708,792, up from AUD3,219,646 a year earlier. Higher closing cash therefore needs to be considered alongside ongoing operating expenditure and financing activity, rather than treated as a measure of operating profitability.

Product Adoption and Execution Considerations

Atomo’s platforms are designed to simplify rapid testing procedures, but technical functionality alone does not establish market uptake. Product orders, manufacturing fulfilment, partner requirements and the regulatory standing of specific test applications are distinct operational considerations. The company’s reported cash use also makes the timing of commercial receipts relevant when assessing its financial disclosures.

For Atomo Diagnostics Limited (ASX:AT1), the distinction between integrating a sampling mechanism and validating a completed diagnostic test is important. Device handling features can address steps in the testing workflow, while disease-specific performance claims require separate evidence. No unverified clinical efficacy, regulatory clearance or future revenue claims are assumed.

Key Insights

Atomo Diagnostics Limited (ASX:AT1) combines an integrated capillary-blood testing platform with a business that reported higher FY26 revenue but continued net and operating cash losses. Its published Galileo specifications explain the intended benefits of sequenced sampling and controlled sample delivery. The FY26 accounts provide a separate measure of commercial progress and financing requirements, without establishing future clinical or financial outcomes.

FAQs

Q:What does Atomo Diagnostics manufacture?

A:It develops integrated rapid diagnostic testing devices and sample-handling technologies.

Q:What is Galileo designed to do?

A:It combines a safety lancet, capillary blood collection and delivery into a sequenced rapid-testing workflow.

Q:How much revenue did Atomo report for FY26?

A:Revenue from ordinary activities was AUD5,333,849, up 41%.

Q:Was Atomo profitable in FY26?

A:No. The company reported a loss after tax attributable to owners of AUD3,513,587.

Q:What cash did Atomo report at 30 June 2026?

A:Cash and cash equivalents totalled AUD3,708,792.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.